Medacta Reports 9.7% Revenue Growth Despite North American Slowdown

Medacta Group reported 9.7% revenue growth in constant currency for the first half of 2026, reaching 368 million euros, as international demand offset a cooling performance in the United States.

The Swiss orthopedic implant manufacturer, which specializes in joint replacement and spine surgery technology, maintained an adjusted EBITDA margin of 27.8% for the period. This resulted in an adjusted EBITDA of 97 million euros.

Geographic Performance Variations

Growth trajectories differed across the company's operating regions during the first six months of the year. While the Asia Pacific and EMEA regions delivered double-digit growth, the North American market saw a 6.6% increase.

According to a Finanzwire report, the slower pace in North America resulted from a general softening of the U.S. market and a deliberate transition in the company's sales channels within its Spine segment.

Full-Year Outlook

The company maintains its target for full-year 2026 revenue growth between 10% and 14% in constant currency, according to data from Investing.com.

This guidance reflects management's view on the demand for its surgical solutions as it navigates structural changes in its U.S. distribution network. Stakeholders are monitoring the company's ability to maintain margins during this transition period to evaluate operational efficiency.